Thermo Fisher Scientific acquires Phadia from Cinven

Life-sciences supply company Thermo Fisher Scientific has signed a definitive agreement to acquire Phadia from European private equity firm Cinven for €2.47bn (£2.18bn) in cash.

The transaction, which is scheduled to be completed in the fourth quarter of 2011, is expected to be immediately accretive to Thermo Fisher’s adjusted earnings per share and accretive by $0.26 to $0.30 per share in 2012.

Based in Uppsala, Sweden, Phadia develops, manufactures and markets complete blood-test systems to support the clinical diagnosis and monitoring of allergy and autoimmune diseases.